Zealand Pharma A/S traded at 280.90 this Monday July 13th, decreasing 1.10 or 0.39 percent since the previous trading session. Looking back, over the last four weeks, Zealand Pharma A/S lost 8.20 percent. Over the last 12 months, its price fell by 23.06 percent. Looking ahead, we forecast Zealand Pharma A/S to be priced at 268.94 by the end of this quarter and at 233.29 in one year, according to Trading Economics global macro models projections and analysts expectations.
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company''s peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.